Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 13:54:52 12/03/2026 GMT			5-day change	1st Jan Change
242.06 ^USD	-0.38%		+0.56%	+16.44%

01:01pm	Johnson & Johnson Says FDA Approves Johnson & Johnson's TECNIS PureSee Lens for Cataract Surgery	MT
03-11	J&J says CEO's 2025 total compensation was $32.8 million	RE

Press Releases

12:04pm	Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients	BU
03-11	Johnson & Johnson : 2026 Proxy Statement	PU
03-11	Johnson & Johnson : Meeting agenda (2026 Agenda for Annual Meeting of Shareholders)	PU
03-11	Johnson & Johnson : Rules of order & FAQ’s (2026 Rules of order and FAQ s)	PU
03-10	European Biosimilar Updates	AQ
03-10	Johnson & Johnson : TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy	PU
03-09	Johnson & Johnson : European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)	PU
03-05	Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line	PR
03-05	Johnson & Johnson : Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line	PU
03-05	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion	PR
03-05	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion	AQ
03-04	Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus	AQ
03-03	/C O R R E C T I O N -- Johnson & Johnson/	PR
03-02	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results	BU
02-26	Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer	PR
02-26	Johnson & Johnson : Completes Catheter Portfolio with Launch of CEREGLIDE™ 42, CEREGLIDE™ 57, and INNERGLIDE™ 7	PU
02-24	Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)	PR
02-24	Bayer takes Johnson & Johnson to court over misleading advertising for prostate cancer drug	AQ
02-23	Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer	PU
02-23	Johnson & Johnson - TREMFYA long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years	AQ
02-21	TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years	PR
02-19	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer	PR
02-18	Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania	BU
02-18	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer	PR
02-17	FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month	PR